Novacyt ( (FR:ALNOV) ) has shared an update.
Novacyt S.A. announced that its non-trading subsidiary, Lab21 Healthcare Ltd, has pleaded guilty to health and safety charges related to its historical operations in Axminster, Devon. The site was part of an acquisition in 2018, and the operations no longer contribute to Novacyt’s ongoing business. The sentencing is scheduled for September 2025, and the company has cooperated with the Health and Safety Executive throughout the investigation.
More about Novacyt
Novacyt is an international molecular diagnostics company that offers a wide range of integrated technologies and services, focusing primarily on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation, providing solutions across sectors such as human health, animal health, and environmental. Novacyt operates through three business segments: Clinical, Instrumentation, and Research Use Only, and has a global presence with offices in France, the UK, Singapore, the US, and Canada.
YTD Price Performance: 2.42%
Average Trading Volume: 326
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $45.56M
For detailed information about ALNOV stock, go to TipRanks’ Stock Analysis page.